Not FDA-approved1,5Evidence: Large human trialsInflammation and immune · Infections

Thymopentin1

Also called Timunox1

Key takeaway

Thymopentin is a synthetic five-amino-acid peptide (Arg-Lys-Asp-Val-Tyr) matching positions 32 to 36 of thymopoietin, and studied as a modulator of the immune system.1 Randomized trials from the 1990s had mixed results: it did not clear chronic hepatitis B or significantly cut infections after surgery, and in a 352-person HIV trial it reduced progression only in people who had already taken AZT for longer.2,3,4 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,5,7

Thymopentin at a glance

What it isA synthetic pentapeptide matching residues 32 to 36 of thymopoietin, also recorded as TP-5 and under the brand names Timunox and Sintomodulina, according to FDA’s substance registry.1
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,5
Human evidenceRandomized trials from the 1990s in HIV infection, chronic hepatitis B and cancer surgery, with mixed results.2,3,4
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is thymopentin?

Thymopentin is a synthetic peptide of five amino acids, arginine, lysine, aspartic acid, valine and tyrosine, matching positions 32 to 36 of thymopoietin.1

FDA’s substance registry also records it as TP-5, thymopoietin pentapeptide and the brand names Timunox, Sintomodulina and Immunox.1

How is thymopentin thought to work?

It was studied as a modulator of the immune system. In the 1994 surgery trial, it prevented the fall in CD3- and CD4-positive T cells after operations in older patients.4

In the 1995 HIV trial it did not change CD4 counts or p24 antigen levels compared with placebo.2

What do human studies show?

A 48-week randomized, double-blind trial in 352 people with HIV taking AZT found fewer cases of AIDS or death with thymopentin among those who had taken AZT for more than six months (2 versus 10), but no significant difference among those who had taken it for less (4 versus 0). Adverse reactions were not more common than with placebo.2

In a randomized trial of 206 people having major surgery for stomach or colorectal cancer, the infection rate was 17.5% with thymopentin and 24.3% without it, a difference that was not significant.4

In a randomized trial of 30 people with chronic hepatitis B, the authors concluded that six months of thymopentin was not effective.3

What the evidence base contains

  • Large randomized human trial A 48-week double-blind, randomized, placebo-controlled trial in 352 people with HIV taking zidovudine (AZT), in which thymopentin reduced progression to AIDS or death among those with longer prior AZT use but not among those with shorter use.2
  • Controlled human trial A randomized controlled trial in 206 people having major cancer surgery, in which thymopentin did not significantly reduce postoperative infections, though infections were less severe in older patients.4
  • Controlled human trial A randomized controlled trial in 30 people with chronic hepatitis B, which concluded that six months of thymopentin was not effective.3

Evidence-strength label: Large randomized human trials. How this label is assigned

Is thymopentin FDA-approved?

None of the sources reviewed here reports an approval of thymopentin by FDA.1,5

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list thymopentin.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymopentin is not among them.6,7

Timeline

  1. Randomized trials of thymopentin in chronic hepatitis B and in cancer surgery are published.3,4
  2. A 352-person randomized trial of thymopentin in people with HIV is published.2

What is still unknown?

Whether the benefit seen in one group of the HIV trial would hold up: in the other group there was no benefit, and HIV treatment has changed since the 1990s.2

Whether it helps any condition reliably: the trials reviewed here had mixed or negative results.3,4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Thymopentin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Thymopentin are a bounded selection, not every registration or paper about Thymopentin. For the years before Thymopentin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Thymopentin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Thymopentin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; studied in clinical trials. A 352-person HIV trial found benefit in one subgroup only; smaller trials in hepatitis B and cancer surgery found no significant benefit. Thymopentin is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Thymopentin?

No FDA approval reported; studied in clinical trials. A 352-person HIV trial found benefit in one subgroup only; smaller trials in hepatitis B and cancer surgery found no significant benefit. Thymopentin is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
9
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    Thymopentin treatment of herpes simplex infections. An open, monitored, multicenter study.↗Source date October 20, 2026
  2. Literature metadata · added November 16, 2026

    Thymopentin in active rheumatoid arthritis. An open, monitored study in 16 patients.↗Source date October 20, 2026
  3. Literature metadata · added November 16, 2026

    Thymopentin treatment in patients with chemotherapy-resistant lepromatous leprosy.↗Source date October 11, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Thymopentin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

32Selected dated records
39Connected citations
9Populated source years2005–2026
2/4Record lanes present

Registered human studies

Trial composition

7 of 7 selected trial records include at least one phase value; 7 of 7 include a status value in the retained structured contract.

PhasesNot applicable 5Phase 2 1Phase 3 1
Status at observationCompleted 7

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 25Clinical Trial 15Randomized Controlled Trial 8Review 7Controlled Clinical Trial 3Comparative Study 2English Abstract 2Research Support, Non-U.S. Gov't 2Multicenter Study 1Research Support, U.S. Gov't, P.H.S. 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
32

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 32 dated records

Research hub

Explore the Thymopentin evidence record

Open all 32 records →
32Dated records
2Evidence types
32Cited public sources
9Source years

Change ledger

Recently changed for Thymopentin

Open all 32 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00002049

PeptideScanner retained ClinicalTrials.gov record NCT00002049 at 2026-11-16T17:32:22.993Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was thymopentin.

PeptideScanner change date
November 16, 2026
Cited source date
June 24, 2005
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00002050

PeptideScanner retained ClinicalTrials.gov record NCT00002050 at 2026-11-16T17:32:22.993Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was thymopentin.

PeptideScanner change date
November 16, 2026
Cited source date
June 24, 2005
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00002051

PeptideScanner retained ClinicalTrials.gov record NCT00002051 at 2026-11-16T17:32:22.993Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was thymopentin.

PeptideScanner change date
November 16, 2026
Cited source date
June 24, 2005
Evidence lane
Clinical trials

Official-source collections

Source records for Thymopentin

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. Self-assembled Palmitic Acid-modified Thymopentin Functions as a Delivery System of Nanovaccine for Cancer Immunotherapy.Chembiochem : a European journal of chemical biology · 2025 02 04
  2. Structural analysis of Salvia miltiorrhiza polysaccharide and its regulatory functions on T cells subsets in tumor-bearing mice combined with thymopentin.International journal of biological macromolecules · 2024 07 11
  3. Preformulation studies of thymopentin: analytical method development, physicochemical properties, kinetic degradation investigations and formulation perspective.Drug development and industrial pharmacy · 2022 03 15
Explore all selected literature →
ClinicalTrials.gov7

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT00002049Registry update June 24, 2005 · completed at observation
  2. NCT00002050Registry update June 24, 2005 · completed at observation
  3. NCT00002051Registry update June 24, 2005 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span June 24, 2005 to October 20, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,5
  • U.S. Department of Health and Human Services6
Dated updates connected to this profile · 32

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Thymopentin treatment of herpes simplex infections. An open, monitored, multicenter study.↗

    PubMed lists PMID 2863860 in Survey of immunologic research as Clinical Trial, Journal Article, with publication-date metadata of 1985 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Thymopentin in active rheumatoid arthritis. An open, monitored study in 16 patients.↗

    PubMed lists PMID 3898297 in Survey of immunologic research as Clinical Trial, Journal Article, with publication-date metadata of 1985 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Thymopentin treatment in patients with chemotherapy-resistant lepromatous leprosy.↗

    PubMed lists PMID 3898294 in Survey of immunologic research as Clinical Trial, Journal Article, with publication-date metadata of 1985 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Thymopentin and splenopentin as immunomodulators. Current status.↗

    PubMed lists PMID 9638477 in Immunologic research as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 1998 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Self-assembled Palmitic Acid-modified Thymopentin Functions as a Delivery System of Nanovaccine for Cancer Immunotherapy.↗

    PubMed lists PMID 39814680 in Chembiochem : a European journal of chemical biology as Journal Article, with publication-date metadata of 2025-02-04 (day precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Structural analysis of Salvia miltiorrhiza polysaccharide and its regulatory functions on T cells subsets in tumor-bearing mice combined with thymopentin.↗

    PubMed lists PMID 39002910 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2024-07-11 (day precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Preformulation studies of thymopentin: analytical method development, physicochemical properties, kinetic degradation investigations and formulation perspective.↗

    PubMed lists PMID 35234086 in Drug development and industrial pharmacy as Journal Article, with publication-date metadata of 2022-03-15 (day precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Tetrahydro-β-carboline-3-carboxyl-thymopentin: a nano-conjugate for releasing pharmacophores to treat tumor and complications.↗

    PubMed lists PMID 32263105 in Journal of materials chemistry. B as Journal Article, with publication-date metadata of 2015-12-24 (day precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Thymopoietin to thymopentin: experimental studies.↗

    PubMed lists PMID 2994196 in Survey of immunologic research as Journal Article, Review, with publication-date metadata of 1985 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Thymopentin treatment of selective IgA deficiency.↗

    PubMed lists PMID 3898285 in Survey of immunologic research as Clinical Trial, Controlled Clinical Trial, Journal Article, with publication-date metadata of 1985 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Immunomodulation with thymopentin: in vitro studies.↗

    PubMed lists PMID 2657246 in Medical oncology and tumor pharmacotherapy as Journal Article, Review, with publication-date metadata of 1989 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Thymopentin in dermatology.↗

    PubMed lists PMID 2663371 in Current problems in dermatology as Journal Article, Review, with publication-date metadata of 1989 (year precision). PeptideScanner associated the retained record with the identity slug thymopentin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Thymopentin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial (1995) · PMID 7859140 ↗

    Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology · Official source · Source checked November 16, 2026

  3. 3
    A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B (1994) · PMID 7836705 ↗

    Journal of Hepatology · Official source · Source checked November 16, 2026

  4. 4
    Impact of thymopentin on the incidence and severity of postoperative infection: a randomized controlled trial (1994) · PMID 8156337 ↗

    The British Journal of Surgery · Official source · Source checked November 16, 2026

  5. 5
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026